158 related articles for article (PubMed ID: 23319146)
1. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
[TBL] [Abstract][Full Text] [Related]
2. ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.
Kacprzyk LA; Laible M; Andrasiuk T; Brase JC; Börno ST; Fälth M; Kuner R; Lehrach H; Schweiger MR; Sültmann H
PLoS One; 2013; 8(3):e59976. PubMed ID: 23555854
[TBL] [Abstract][Full Text] [Related]
3. The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker.
Xiao L; Lanz RB; Frolov A; Castro PD; Zhang Z; Dong B; Xue W; Jung SY; Lydon JP; Edwards DP; Mancini MA; Feng Q; Ittmann MM; He B
Prostate; 2016 Oct; 76(14):1271-84. PubMed ID: 27272765
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
6. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
7. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
8. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
Smit FP; Salagierski M; Jannink S; Schalken JA
BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
11. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
12. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.
Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J
Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826
[TBL] [Abstract][Full Text] [Related]
13. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ
Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
[TBL] [Abstract][Full Text] [Related]
16. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.
Massoner P; Kugler KG; Unterberger K; Kuner R; Mueller LA; Fälth M; Schäfer G; Seifarth C; Ecker S; Verdorfer I; Graber A; Sültmann H; Klocker H
PLoS One; 2013; 8(2):e55207. PubMed ID: 23390522
[TBL] [Abstract][Full Text] [Related]
17. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.
Gasi Tandefelt D; Boormans JL; van der Korput HA; Jenster GW; Trapman J
Eur Urol; 2013 Dec; 64(6):941-50. PubMed ID: 23490727
[TBL] [Abstract][Full Text] [Related]
18. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
[TBL] [Abstract][Full Text] [Related]
19. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
20. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
